GlassScriptPhysician profile
Fredric C Cogan
NPI 1649289968
$15,085.45
in general payments reported to CMS, 2019-2025
21 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,891 · 2020: $2,184 · 2021: $2,368 · 2022: $2,227 · 2023: $2,296 · 2024: $1,629 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,321 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,320.92 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,062.72 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Amgen INC. | $3,708.12 | 2019-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $1,375.99 | 2019-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $1,169.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,088.61 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $879.56 | 2019-2022 | |
| Astellas Pharma US INC | $775.47 | 2019-2023 | Myrbetriq, Veozah |
| Amarin Pharma, INC. | $373.68 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $360.92 | 2019 | |
| Pfizer INC. | $228.33 | 2019-2021 | |
| Esperion Therapeutics, INC. | $217.49 | 2021-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $181.48 | 2019-2023 | Dupixent |
| Novo Nordisk INC | $181.44 | 2020-2023 | Rybelsus |
| Merck Sharp & Dohme LLC | $158.73 | 2019-2021 | |
| Intuity Medical INC | $131.85 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $60.50 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $38.23 | 2023 | Seglentis |
| Abbvie INC. | $34.23 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Kaleo, INC. | $19.66 | 2019 | |
| Smith+Nephew, INC. | $17.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredric Cogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.